Avadel Pharmaceuticals (NASDAQ:AVDL) Downgraded to “Hold” Rating by Leerink Partnrs

Leerink Partnrs lowered shares of Avadel Pharmaceuticals (NASDAQ:AVDL) from a strong-buy rating to a hold rating in a research note issued to investors on Thursday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2026 earnings at $0.73 EPS and FY2027 earnings at $1.23 EPS.

Other equities analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avadel Pharmaceuticals in a research note on Wednesday, October 8th. Lifesci Capital raised shares of Avadel Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, September 3rd. Leerink Partners reaffirmed a “market perform” rating and issued a $18.50 price objective on shares of Avadel Pharmaceuticals in a report on Thursday. Wells Fargo & Company upgraded shares of Avadel Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 3rd. Finally, Needham & Company LLC lowered shares of Avadel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Three investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $18.72.

Avadel Pharmaceuticals Price Performance

Shares of AVDL stock opened at $18.56 on Thursday. The company has a market capitalization of $1.80 billion, a P/E ratio of -618.67 and a beta of 1.46. The company’s 50-day simple moving average is $15.21 and its two-hundred day simple moving average is $11.50. Avadel Pharmaceuticals has a one year low of $6.38 and a one year high of $18.65.

Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its earnings results on Thursday, August 7th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.08. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The business had revenue of $68.13 million for the quarter, compared to the consensus estimate of $60.28 million. During the same period in the prior year, the firm earned ($0.14) EPS. The company’s revenue for the quarter was up 64.1% compared to the same quarter last year. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Avadel Pharmaceuticals will post -0.51 EPS for the current fiscal year.

Institutional Trading of Avadel Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC lifted its stake in shares of Avadel Pharmaceuticals by 164.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $29,000 after purchasing an additional 2,055 shares during the period. State of Alaska Department of Revenue acquired a new stake in shares of Avadel Pharmaceuticals in the third quarter valued at about $83,000. Raymond James Financial Inc. acquired a new stake in shares of Avadel Pharmaceuticals in the second quarter valued at about $65,000. Tower Research Capital LLC TRC lifted its stake in shares of Avadel Pharmaceuticals by 217.5% in the second quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company’s stock valued at $78,000 after purchasing an additional 6,025 shares during the period. Finally, Exencial Wealth Advisors LLC acquired a new stake in shares of Avadel Pharmaceuticals in the first quarter valued at about $82,000. Institutional investors and hedge funds own 69.19% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.